Processa (PCSA) Amendment Shows 38,727-Share Sale and Trust Ownership

Rhea-AI Filing Summary

Processa Pharmaceuticals insider amendment reports a corrected sale and existing family trust holdings. The filing amends a prior Form 4 to retract an earlier filing error and discloses a disposition of 38,727 shares of common stock reported as a sale. Following the reported transaction the reporting person is shown as beneficially owning 43,500 shares indirectly through the Lin Family Trust. The reporting person is an officer

Positive

• None.

Negative

• Correction of prior filing indicates an earlier reporting error requiring amendment
• Disposition of 38,727 shares reduces the reporting person's direct common stock holdings

Insights

Securities Compliance Analyst

TL;DR Amendment corrects prior filing; shows a stock disposal and ongoing indirect trust ownership—procedural compliance matter.

The amendment indicates the original Form 4 was filed in error and has been retracted, which is a remedial compliance action to ensure accurate Section 16 reporting. The substantive disclosure is a disposition of 38,727 common shares and retained indirect beneficial ownership of 43,500 shares via the Lin Family Trust. There are no derivative instruments reported. For investors, this is primarily a transparency and governance item rather than a new operational development.

Corporate Governance Specialist

TL;DR Officer/director corrected insider report; sale reduces direct holding while trust retains stake—minor governance signal.

The reporting person serves as both an officer and director, and the amendment rectifies prior disclosure. The disclosed sale of 38,727 shares reduces direct ownership; an indirect holding of 43,500 shares remains through a family trust. This filing addresses accuracy in insider disclosure obligations; it does not present new strategic or financial information about the company itself.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Lin Patrick

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FL 32960

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business - Strategy Off

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/28/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								38,727	D
Common Stock								43,500	I	Lin Family Trust Feb 4, 2024

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Amendment filed to retract the prior Form 4, which was filed in error.

	/s/ Patrick Lin by John J. Wolfel, as Attorney-in-Fact	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did the Form 4/A for PCSA disclose?

The amendment discloses a disposition of 38,727 shares of common stock and shows 43,500 shares held indirectly via the Lin Family Trust.

Why was this Form 4 amended for PCSA?

The filing states the prior Form 4 was filed in error and the amendment retracts that prior filing to correct the record.

Does the amendment report any derivative or option activity for PCSA?

No. The amendment contains no reported derivative securities, exercises, or expiration details.

What is the reporting person's role at Processa Pharmaceuticals (PCSA)?

The reporting person is listed as a director and an officer with the title Chief Business - Strategy Officer.

Is the disclosed ownership direct or indirect?

The 38,727-share disposition pertains to direct holdings, while the 43,500 shares are reported as indirect beneficial ownership through the Lin Family Trust.